SCHEMBL4347168

SCHEMBL4347168

Cc1cccc(C)c1NC(=O)Nc1ccc(O)c([N+](=O)[O-])c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.61
MEN1 O00255 6/20 0.61
MAPT P10636 5/20 0.61
LMNA P02545 5/20 0.61
NPC1 O15118 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
RAB9A P51151 2/20 0.61
MAPK1 P28482 1/20 0.61
ALDH1A1 P00352 1/20 0.56
TRPV1 Q8NER1 1/20 0.52
HTT P42858 4/20 0.51
GAA P10253 1/20 0.51
DDX3X O00571 2/20 0.51
KCNMA1 Q12791 1/20 0.51
POLB P06746 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
EGFR P00533 1/20 0.47
IDH1 O75874 2/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6668451 0.90 RAB9A (0.58) KMT2AMEN1MAPTLMNANPC1
SCHEMBL4354193 0.87 DDX3X (0.65) KMT2AMEN1MAPTLMNANPC1
SCHEMBL4341820 0.83 MAPT (0.72) KMT2AMEN1MAPTLMNANPC1
SCHEMBL4342380 0.81 CA12 (0.64) KMT2AMEN1MAPTLMNANPC1
SCHEMBL4356006 0.80 NPC1 (0.57) KMT2AMEN1MAPTLMNANPC1
SCHEMBL4954984 0.80 KMT2A (0.70) KMT2AMEN1MAPTLMNANPC1
SCHEMBL11326938 0.79 KMT2A (0.85) KMT2AMEN1MAPTLMNANPC1
SCHEMBL11591038 0.79 KCNMA1 (0.65) KMT2AMEN1MAPTLMNANPC1
SCHEMBL6975308 0.79 MAPT (0.54) KMT2AMEN1MAPTLMNANPC1
SCHEMBL6975312 0.79 MAPT (0.54) KMT2AMEN1MAPTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KMT2A 2096/4885MEN1 2168/4885MAPT 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.